.png){kind=icon}
.png){kind=icon}
Return
Targeted Blood-Brain Barrier Penetration for Traumatic Brain Injury Therapy via RXR/PPAR-Driven Microglial M2 Polarization
.png){kind=icon}
OA
AI
S
J
X
L
Z
X
D
L
L
DOI：10.1016/j.mtbio.2026.103552.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
As a leading global cause of death and disability, traumatic brain injury (TBI) triggers a complex secondary injury process leading to long-term neurological impairment. Current therapeutic efficacy is limited by the blood-brain barrier (BBB) and the absence of integrated approaches to address neuroinflammation and neuroregeneration. We designed a biomimetic nanomedicine (Ali-NPs@Mexo) by encapsulating alitretinoin(Ali)-loaded albumin nanospheres within mesenchymal stromal cell (MSC)-derived exosomal membranes. This platform exploits the natural BBB-crossing and inflammation-targeting capabilities of exosomes to enhance localized drug delivery. Mechanistic studies revealed that Ali-NPs@Mexo triggers RXR/PPAR signaling to promote M1-to-M2 microglial polarization, thereby mitigating acute inflammation. Moreover, it protects neurons by inhibiting reactive astrogliosis and supporting the growth of neural stem cells and oligodendrocytes. In vivo, Ali-NPs@Mexo significantly improved functional and cognitive outcomes in mice. This integrated strategy of targeted immune-modulation and neuro-regeneration provides a translatable framework for effective TBI intervention.
Keywords:
Traumatic brain injury
Exosomes
Alitretinoin
Nerve repair
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.2
Papers:
3.6K
Citations:
9.5K
Organization
Cited Papers